<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277703</url>
  </required_header>
  <id_info>
    <org_study_id>1077651</org_study_id>
    <nct_id>NCT03277703</nct_id>
  </id_info>
  <brief_title>Flu Vaccine Response in Patients on Biologic Therapies</brief_title>
  <official_title>Booster Vaccine Strategy to Improve Serologic Responses to Influenza Vaccination in Children With Rheumatic Diseases and Inflammatory Bowel Disease Who Are Receiving Immunosuppressive Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed study will assess the immunogenicity, safety, and clinical efficacy of an
      influenza vaccine booster dose strategy in patients with autoimmune diseases who are
      receiving immunosuppressive therapies. Investigators will compare serologic responses to
      single versus a booster dose of influenza vaccine in patients with inflammatory bowel disease
      (IBD- Crohn's Disease or Ulcerative Colitis) or rheumatologic diseases who are receiving
      immunosuppressive therapies. Subjects will be randomized to receive either one or two doses
      of influenza vaccination in year #1. In year# 2, all participants will be given two doses of
      influenza vaccine. Serologic responses will be measured pre and 4-6 weeks post vaccination.
      This study will also assess the immunogenicity and safety of a booster vaccine strategy in
      the prevention of influenza-like illness (ILI). Investigators anticipate that booster dose
      strategy will improve both clinical and serologic responses in this vulnerable population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influenza hemagglutination inhibition (HAI) titer</measure>
    <time_frame>4 weeks post vaccination</time_frame>
    <description>immunological vaccine response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of vaccine</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>decreased influenza rates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Rheumatologic Disorder</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Immune Complex Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1 - Booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.
Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population</description>
    <arm_group_label>Group 1 - Booster</arm_group_label>
    <arm_group_label>Group 2 - Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children ages 3-22 years

          -  Rheumatologic condition (JIA, Uveitis, SLE and other rheumatologic disorders) or
             inflammatory bowel disease (Crohn's disease or ulcerative colitis) and who are
             receiving immunosuppressive therapies as follows:

               -  TNF inhibitors [etanercept (Enbrel), adalimumab (Humira®), infliximab
                  (Remicade®)]

               -  anti IL -1 [anakinra (Kineret®) or canakinumab (Ilaris®)]

               -  IL-6 tocilizumab (Actemra®)

               -  anti IL-12/23 ustekinumab (Stelara®)

               -  anti CTLA-4 [abatacept (Orencia®)]

               -  vedolizumab (Entyvio®)

               -  azathioprine (Imuran®)

               -  6 mercaptopurine (Purinethol®)

               -  Cyclosporine

               -  Leflunomide

               -  Mycophenolate

               -  methotrexate (Otrexup® or Rasuvo®)

        Exclusion Criteria:

          -  Prior allergic reaction to any vaccine components

          -  Other contraindication to influenza vaccination

          -  Severe egg allergy

          -  Pregnancy

          -  Prior Guillain-Barre syndrome

          -  Therapy with oral corticosteroids ≥2 mg/mg/day within 4 weeks of study entry

          -  Prior rituximab

          -  Prior cyclophosphamide

          -  Prior IVIG within 8 weeks

          -  Acute febrile illness at time of study evaluation

          -  No prior history of two doses of influenza in the past for ages 3-8 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christy A Beneri, DO</last_name>
    <phone>(631) 444-7692</phone>
    <email>Christy.Beneri@stonybrookmedicine.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Cherian, MD</last_name>
    <phone>(631) 444-7884</phone>
    <email>Julie.Cherian@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Mattias, RN</last_name>
      <phone>631-444-6900</phone>
      <email>wendy.mattias@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Walters HM, Pan N, Lehman TJ, Adams A, Huang WT, Sitaras L, Cunningham-Rundles S, Walsh TJ, Toussi SS. A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors. Clin Rheumatol. 2015 Mar;34(3):457-64. doi: 10.1007/s10067-014-2779-8. Epub 2014 Sep 18.</citation>
    <PMID>25227771</PMID>
  </reference>
  <reference>
    <citation>Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis. 2013 Nov;57(9):1318-30. doi: 10.1093/cid/cit489. Epub 2013 Jul 29. Review.</citation>
    <PMID>23899685</PMID>
  </reference>
  <reference>
    <citation>Carvalho LM, de Paula FE, Silvestre RV, Roberti LR, Arruda E, Mello WA, Ferriani VP. Prospective surveillance study of acute respiratory infections, influenza-like illness and seasonal influenza vaccine in a cohort of juvenile idiopathic arthritis patients. Pediatr Rheumatol Online J. 2013 Mar 7;11:10. doi: 10.1186/1546-0096-11-10. eCollection 2013.</citation>
    <PMID>23510667</PMID>
  </reference>
  <reference>
    <citation>Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, Duarte A, Miraglia JL, Timenetsky Mdo C, Viana VS, França IL, Bonfa E, Pereira RM. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012 Jan;39(1):167-73. doi: 10.3899/jrheum.110721. Epub 2011 Nov 15.</citation>
    <PMID>22089462</PMID>
  </reference>
  <reference>
    <citation>Flannery B, Reynolds SB, Blanton L, Santibanez TA, O'Halloran A, Lu PJ, Chen J, Foppa IM, Gargiullo P, Bresee J, Singleton JA, Fry AM. Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010-2014. Pediatrics. 2017 May;139(5). pii: e20164244. doi: 10.1542/peds.2016-4244. Epub 2017 Apr 3.</citation>
    <PMID>28557757</PMID>
  </reference>
  <reference>
    <citation>Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J. 2011 Mar;30(3):208-11. doi: 10.1097/INF.0b013e3181f7ce44.</citation>
    <PMID>20861757</PMID>
  </reference>
  <reference>
    <citation>deBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, Kaplan GG, Seow CH, Wrobel I. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. Inflamm Bowel Dis. 2016 Mar;22(3):638-47. doi: 10.1097/MIB.0000000000000615.</citation>
    <PMID>26595551</PMID>
  </reference>
  <reference>
    <citation>Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavaldà J, Moreno A, Torre-Cisneros J, Montejo JM, Fortun J, Muñoz P, Sabé N, Fariñas MC, Blanes-Julia M, López-Medrano F, Suárez-Benjumea A, Martinez-Atienza J, Rosso-Fernández C, Pérez-Romero P; TRANSGRIPE 1–2 Study Group. Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. Clin Infect Dis. 2017 Apr 1;64(7):829-838. doi: 10.1093/cid/ciw855.</citation>
    <PMID>28362949</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Christy Beneri</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <keyword>Booster dose</keyword>
  <keyword>immunocompromised</keyword>
  <keyword>Biologic therapy</keyword>
  <keyword>Rheumatologic disease</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Immune Complex Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

